Serious adverse events · people with chronic gout
Allopurinol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · Patients with ileal pouch‐anal anastomosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · participants with chronic prostatitis/chronic pelvic pain syndrome
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Allopurinol showed no clear difference in withdrawal due to adverse events compared with benzbromarone (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Allopurinol showed no clear difference in withdrawal due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Other adverse events and complications · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
Total adverse events · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Total adverse events · people with chronic gout
Benzbromarone showed no clear difference in total adverse events compared with allopurinol (low certainty).
1 finding from 1 review
Serious adverse events · people with chronic gout
Febuxostat 40 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).
1 finding from 1 review
Serious adverse events · people with chronic gout
Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (moderate certainty).
1 finding from 1 review
Serious adverse events · people with chronic gout
Febuxostat 120 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).
1 finding from 1 review
Frequency of adverse events ( · children with haematological malignancy at risk of tumour lysis syndrome
Summary of findings: urate oxidase may leads to higher frequency of adverse events ( compared with allopurinol (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Benzbromarone showed no clear difference in withdrawal due to adverse events compared with allopurinol (low certainty).
1 finding from 1 review
Total adverse events ‐ not reported · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Other adverse events and complications · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Withdrawals due to adverse events ‐ not reported · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review